Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Artivion (DE:CYL)
FRANKFURT:CYL
Artivion (CYL) Stock Price & Analysis
0 Followers
CYL Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€11.70 - €19.94
Previous Close€18.84
Volume0.00
Average Volume (3M)140.00
Market Cap
€801.64M
Enterprise Value€1.08B
Total Cash (Recent Filing)$58.94M
Total Debt (Recent Filing)$358.34M
Price to Earnings (P/E)N/A
Beta1.05
Next Earnings
May 06, 2024EPS Estimate
-€0.11Last Dividend Ex-Date
Dec 09, 2015Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,225,138
10 Day Avg. Volume0
30 Day Avg. Volume140
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-6.15
Price to Sales (P/S)2.19
Price to Cash Flow (P/CF)19.60
P/FCF Ratio4.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.05
Enterprise Value/Gross Profit4.72
Enterprise Value/Ebitda40.36
Forecast
1Y Price Target
€23.31Price Target Upside23.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Artivion News
PremiumThe Fly
Artivion rises 7.6%
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPositive full data from the PERSEVERE study of AMDS presented at a significant medical conference showed a substantial reduction in mortality and adverse events, bolstering confidence in its potential FDA approval.
Executive AppointmentLance Berry is set to take over as CFO, bringing a positive reputation from his tenure at Wright Medical, which may instill investor confidence in the company's future financial leadership.
GuidanceThe Company provided revenue guidance for the next year that exceeds market expectations, indicating a strong financial outlook.
Bears Say
Executive Team ChangeCFO Ashley Lee, having steered the company through significant growth, is set to retire, potentially leading to uncertainties in financial leadership.
Financial ForecastAdjusted EBITDA guidance for the next year falls short of market analysts' expectations.
Financial PerformanceAnalysts express concern as the company's projected EBITDA does not align with the expected market consensus.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
2.79% Other Institutional Investors
97.21% Public Companies and
Individual Investors
CYL FAQ
What was Artivion’s price range in the past 12 months?
Artivion lowest stock price was €11.70 and its highest was €19.94 in the past 12 months.
What is Artivion’s market cap?
Currently, no data Available
When is Artivion’s upcoming earnings report date?
Artivion’s upcoming earnings report date is May 06, 2024 which is in 8 days.
How were Artivion’s earnings last quarter?
Artivion released its earnings results on Feb 15, 2024. The company reported -€0.093 earnings per share for the quarter, missing the consensus estimate of -€0.08 by -€0.013.
Is Artivion overvalued?
According to Wall Street analysts Artivion’s price is currently Undervalued.
Does Artivion pay dividends?
Artivion pays a Quarterly dividend of €0.03 which represents an annual dividend yield of N/A. See more information on Artivion dividends here
What is Artivion’s EPS estimate?
Artivion’s EPS estimate is -€0.11.
How many shares outstanding does Artivion have?
Currently, no data Available
What happened to Artivion’s price movement after its last earnings report?
Artivion reported an EPS of -€0.093 in its last earnings report, missing expectations of -€0.08. Following the earnings report the stock price went up 3.067%.
Which hedge fund is a major shareholder of Artivion?
Among the largest hedge funds holding Artivion’s share is Royce & Associates LLC. It holds Artivion’s shares valued at 19M.
---
Artivion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€23.31 (23.70% Upside)
€23.31 (23.70% Upside)
Blogger Sentiment
Bullish
DE:CYL Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.57%
12-Months-Change
Fundamentals
Return on Equity
-10.80%
Trailing 12-Months
Asset Growth
3.88%
Trailing 12-Months
Company Description
Artivion
CryoLife, Inc. engages in the manufacture, process and distribution of medical devices. It operates through the following segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of BioGlue; JOTEC products, On-X products, CardioGenesis cardiac laser therapy, PerClot and PhotoFix. The Preservation Services segment focuses on external services revenues from the preservation of cardiac and vascular tissues. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.
---
CYL Company Deck
---
CYL Earnings Call
Q4 2024
0:00 / 0:00
---
CYL Stock 12 Months Forecast
Average Price Target
€23.31
▲(23.70% Upside)
Technical Analysis
Best Analysts Covering CYL
1 Year
1 Year Success Rate
19/31 ratings generated profit
1 Year Average Return
+9.08%
reiterated a buy rating 2 months ago
Copying Suraj Kalia's trades and holding each position for 1 Year would result in 61.29% of your transactions generating a profit, with an average return of +9.08% per trade.
---